Meloxicam Inclusion Complex with Rizatriptan for Rapid Migraine Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and slow onset of pain relief, which is exacerbated by inadequate response to prior migraine treatments.
Innovation Solution
A combination of meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD) and bicarbonate, forming an inclusion complex, to enhance solubility and bioavailability, administered with rizatriptan for rapid and sustained pain relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If meloxicam is administered alone, then the drug structure is simple, but the aqueous solubility is poor and bioavailability is reduced
Solution Approach 1:
Cyclodextrins serve as intermediary molecules that form inclusion complexes with meloxicam. The cyclodextrin cavity accommodates the hydrophobic meloxicam molecule, while the hydrophilic exterior of the cyclodextrin interacts with aqueous environments, thereby enhancing solubility without requiring complex formulation techniques
Solution Approach 2:
The patent creates a composite system consisting of meloxicam encapsulated within cyclodextrin molecules. This composite inclusion complex combines the therapeutic properties of meloxicam with the solubility-enhancing characteristics of cyclodextrins, achieving both simplicity and effectiveness
2Speed
If meloxicam is administered alone, then the dosage form is simple, but the onset of pain relief is slow
Solution Approach 1:
Cyclodextrins act as mediators that facilitate faster dissolution and absorption of meloxicam by improving its aqueous solubility. The inclusion complex allows rapid release of meloxicam in the gastrointestinal tract, accelerating the onset of therapeutic effect without complicating the dosage form
Solution Approach 2:
The patent changes the physical-chemical parameters of meloxicam by forming an inclusion complex, which alters its dissolution rate and bioavailability. This parameter change enables faster onset of action while maintaining a simple oral dosage form
3Reliability
If meloxicam is used for migraine treatment, then the anti-inflammatory effect is achieved, but the response is inadequate compared to dedicated migraine treatments
Solution Approach 1:
The patent merges meloxicam with cyclodextrins in a single dosage form, combining the anti-inflammatory effects of NSAIDs with the solubility-enhancing properties of cyclodextrins. This unified approach improves migraine treatment efficacy while simplifying the treatment regimen to a single oral administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination provides rapid and sustained pain relief, reducing migraine symptoms within minutes to hours, and significantly outperforms individual components in efficacy and reducing the need for rescue medication.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
Cyclodextrins are hydrophobic on the inside and hydrophilic on the inside which helps to facilitate the transport of molecules
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.